Amneal (AMRX) CFO earns 458,716 performance RSUs, with shares withheld for taxes

Rhea-AI Filing Summary

Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported multiple equity award vestings and related share issuances. On March 3 and 4, 2026, restricted stock units and performance-based restricted stock units were exercised and converted into shares of Class A Common Stock at no exercise price.

A performance-based grant of 458,716 performance-based restricted stock units from a March 3, 2023 award vested at 200% of its targeted amount after share-price conditions were met and was settled one-for-one into Class A shares. Across the transactions, portions of the newly issued shares, including amounts such as 229,817 shares at $13.31 and other blocks at prices around $13.30–$13.31, were withheld to cover tax withholding obligations, rather than sold in open-market trades. Following these events, Konidaris directly held 449,434 shares of Class A Common Stock as of the latest reported transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Konidaris Tasos

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/03/2026		M		45,290(1)	A	(2)	167,442	D
Class A Common Stock	03/03/2026		F		16,182(3)	D	$13.31	151,260	D
Class A Common Stock	03/03/2026		M		57,339(1)	A	(2)	208,599	D
Class A Common Stock	03/03/2026		F		24,251(3)	D	$13.31	184,348	D
Class A Common Stock	03/03/2026		M		28,538(1)	A	(2)	212,886	D
Class A Common Stock	03/03/2026		F		14,298(3)	D	$13.31	198,588	D
Class A Common Stock	03/03/2026		M		458,716	A	(4)	657,304	D
Class A Common Stock	03/03/2026		F		229,817(5)	D	$13.31	427,487	D
Class A Common Stock	03/04/2026		M		43,982(1)	A	(2)	471,469	D
Class A Common Stock	03/04/2026		F		22,035(3)	D	$13.3	449,434	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/03/2026		M			45,290	(6)	(6)	Class A Common Stock	45,290	$0	0	D
Restricted Stock Units	(2)	03/03/2026		M			57,339	(7)	(7)	Class A Common Stock	57,339	$0	57,340	D
Restricted Stock Units	(2)	03/03/2026		M			28,538	(8)	(8)	Class A Common Stock	28,538	$0	85,617	D
Performance-Based Restricted Stock Units	(4)	03/03/2026		M			458,716	(4)	(4)	Class A Common Stock	458,716	$0	0	D
Restricted Stock Units	(2)	03/04/2026		M			49,982	(9)	(9)	Class A Common Stock	49,982	$0	87,963	D

Explanation of Responses:

1. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

3. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

4. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

5. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

6. On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

7. On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

8. On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

9. On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Amneal (AMRX) CFO Tasos Konidaris report?

Tasos Konidaris reported the vesting and exercise of several restricted stock unit and performance-based restricted stock unit awards, which converted into Class A Common Stock. Some of the newly issued shares were withheld to satisfy tax withholding obligations instead of being sold in the open market.

How many performance-based restricted stock units vested for Amneal (AMRX) CFO?

A grant of 458,716 performance-based restricted stock units vested for the CFO after meeting share-price performance conditions. These units, granted on March 3, 2023, vested at 200% of the targeted number and were settled into an equal number of Class A Common Stock shares.

Were any of the Amneal (AMRX) CFO’s reported share dispositions open-market sales?

The dispositions reported were shares withheld to satisfy tax withholding obligations related to vesting events, not open-market sales. For example, 229,817 shares of Class A Common Stock were withheld at $13.31 per share specifically to cover tax liabilities arising from performance-based restricted stock unit vesting.

How many Amneal (AMRX) Class A shares does the CFO hold after these transactions?

After the reported vesting, conversions, and tax-withholding share reductions, Tasos Konidaris directly held 449,434 shares of Amneal Class A Common Stock. This figure reflects the balance following the latest tax-withholding disposition recorded on March 4, 2026, in the non-derivative transaction table.

What are the key terms of the Amneal (AMRX) performance-based RSUs granted to the CFO?

The performance-based restricted stock units granted on March 3, 2023 vest based on average closing prices of Class A Common Stock over a three-year period. Upon certification that thresholds were met, 200% of the targeted number vested and were settled one-for-one into Class A Common Stock.

What time-based restricted stock unit grants has the Amneal (AMRX) CFO received?

The CFO was granted 181,159 restricted stock units on March 3, 2022, 229,358 on March 3, 2023, 114,155 on March 3, 2025, and 175,926 on March 4, 2024. Each grant vests in four equal installments beginning on the first anniversary of its respective grant date.